Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rifampicin + sulfamethoxazole is a combination of two antibacterial agents, rifampicin and sulfamethoxazole. Rifampicin is a rifamycin antibiotic that inhibits bacterial DNA-dependent RNA polymerase, thereby suppressing RNA synthesis and leading to bactericidal activity. Sulfamethoxazole is a sulfonamide antibiotic that inhibits dihydropteroate synthase in the folate synthesis pathway, resulting in impaired bacterial DNA replication and cell growth. This combination has demonstrated synergistic or additive effects against certain bacteria, including Mycobacterium tuberculosis and methicillin-resistant Staphylococcus aureus (MRSA), with studies showing enhanced efficacy compared to monotherapy[2][1]. The combination may be considered as an alternative regimen for multidrug-resistant infections where standard therapies are not suitable or effective[2][1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on rifampicin + sulfamethoxazole.